Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Rating Lowered by Wall Street Zen

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Several other analysts also recently commented on BAYRY. The Goldman Sachs Group raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Hsbc Global Res raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, June 11th. Finally, Kepler Capital Markets upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Wednesday, June 11th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy".

Bayer Aktiengesellschaft Stock Performance

Shares of Bayer Aktiengesellschaft stock traded up $0.33 on Friday, hitting $7.97. The stock had a trading volume of 293,374 shares, compared to its average volume of 459,926. Bayer Aktiengesellschaft has a 52-week low of $4.79 and a 52-week high of $8.58. The company has a current ratio of 1.25, a quick ratio of 0.79 and a debt-to-equity ratio of 1.07. The stock has a market cap of $31.32 billion, a price-to-earnings ratio of -8.66 and a beta of 0.86. The company's 50 day moving average price is $7.25 and its 200 day moving average price is $6.27.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. Bayer Aktiengesellschaft had a positive return on equity of 13.94% and a negative net margin of 7.26%. The business had revenue of $15.27 billion during the quarter, compared to the consensus estimate of $13.39 billion. On average, research analysts anticipate that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.